<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02464501</url>
  </required_header>
  <id_info>
    <org_study_id>HIPG-CLIN-2015-02</org_study_id>
    <nct_id>NCT02464501</nct_id>
  </id_info>
  <brief_title>The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee</brief_title>
  <acronym>COPPER-A</acronym>
  <official_title>The COPPER-A Trial: The Occlusion Perfusion Catheter for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Horizons International Peripheral Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Advanced Catheter Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Horizons International Peripheral Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of paclitaxel administration
      using the occlusion perfusion catheter (OPC) for the prevention of restenosis in
      infrainguinal de novo, restenotic femoropopliteal and infrapopliteal stenoses and occlusions,
      and in-stent restenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of paclitaxel administration
      using the occlusion perfusion catheter (OPC) for the prevention of restenosis in
      infrainguinal de novo, restenotic femoropopliteal and infrapopliteal stenoses and occlusions,
      and in-stent restenosis. Subjects will be treated with the endovascular intervention selected
      by the treating physician in SFA reference vessels ranging from 4mm to 7mm in diameter and
      infrapopliteal vessels ranging from 2mm to 4mm. Following the achievement of optimal
      interventional results (less than thirty (30) percent residual stenosis without stenting) the
      OPC will be placed at the interventional treatment area and paclitaxel will be delivered to
      the treated segment. Data will be collected to assess acute safety, long-term safety and
      durability to demonstrate the safety and efficacy of paclitaxel delivered with the ACT, Inc.
      OPC device.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Patency</measure>
    <time_frame>12 months</time_frame>
    <description>Measured by duplex Doppler ultrasound (DUS) - demonstrated by Peak Systolic Velocity Ratio (PSVR) ≤ 2.5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from major adverse events (MAEs)</measure>
    <time_frame>1 month</time_frame>
    <description>MAEs are defined as target limb related death, major amputation in the target limb (amputation above the metatarsals), or target lesion revascularization (TLR) within one (1) month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary Patency</measure>
    <time_frame>6 and 24 months</time_frame>
    <description>Measured by duplex Doppler ultrasound (DUS) - demonstrated by Peak Systolic Velocity Ratio (PSVR) ≤ 2.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Rutherford category</measure>
    <time_frame>3, 6, 12, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Assisted Patency</measure>
    <time_frame>1, 3, 6, 12, and 24 months</time_frame>
    <description>Patency of the target lesion following endovascular re-intervention of the target lesion due to symptomatic restenosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Patency</measure>
    <time_frame>1, 3, 6, 12, and 24 months</time_frame>
    <description>Measured by patency of the target lesion after treatment of a (re)occlusion of the index lesion during the follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from target lesion revascularization (TLR)</measure>
    <time_frame>3, 6, 12, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from target vessel revascularization (TVR)</measure>
    <time_frame>3, 6, 12, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Walking Impairment Questionnaire scores</measure>
    <time_frame>6, 12, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>Day 1 - Index Procedure</time_frame>
    <description>Defined as the ability to deliver paclitaxel to the interventional treatment length as intended.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from major adverse events (MAEs)</measure>
    <time_frame>1, 3, 6, 12, 18, and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticipated adverse events</measure>
    <time_frame>1, 3, 6, 12, 18, and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Peripheral Vascular Disease</condition>
  <arm_group>
    <arm_group_label>OPC Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel administration using the OPC for the prevention of restenosis in infrainguinal de novo and restenotic femoropopliteal lesions. Subjects will be treated with the endovascular intervention selected by the treating physician in reference vessels ranging from 4mm to 7mm in diameter. Following the achievement of optimal interventional results (less than thirty (30) percent residual stenosis without stenting) the OPC will be placed at the interventional treatment area and paclitaxel will be delivered to the treated segment. Data will be collected to assess acute safety, long-term safety and durability to demonstrate the safety and efficacy of paclitaxel delivered with the ACT, Inc. OPC device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Paclitaxel administration using the OPC</intervention_name>
    <arm_group_label>OPC Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          -  Willing and able to provide informed consent and comply with all study requirements;

          -  Candidate for peripheral vascular femoropopliteal or infrapopliteal percutaneous
             intervention;

          -  Must be ≥ 18 years of age;

          -  Rutherford category 2, 3, 4, or 5;

          -  Willing and able to tolerate dual anti-platelet therapy (DAPT) for a minimum of one
             (1) month;

          -  Lab work within acceptable limits according to standard of care;

          -  INR &lt; 2.0 if on warfarin or not on warfarin;

          -  Minimum sheath size used for the interventional procedure

               -  7x8 OPC Catheter - 7FR.

               -  3x15 OPC, 3x15 PRESSANA(TM), or 3x8 PRESSANA(TM) - 6FR.

        General Exclusion Criteria:

          -  Life expectancy &lt; three (3) years;

          -  Planned amputation prior to procedure;

          -  Pregnancy or nursing (a pregnancy test is required for all women of childbearing
             capabilities ≤ 7 days prior to the index procedure);

          -  Previous intervention of the target lesion with a drug eluting balloon or drug
             delivery catheter;

          -  Any treatment in the target vessel with drug eluting balloon;

          -  Acute limb ischemia

          -  Known allergy to paclitaxel;

          -  Known hypersensitivity to other drugs manufactured in Cremophor® EL (polyoxyethylated
             castor oil; e.g. Drugs containing polyoxyethylated castor oil are drugs such as
             miconazole, cyclosporine injection, nelfinavir mesylate, saperconazole, tacrolimus,
             and xenaderm ointment);

          -  Known allergy to anticoagulants;

          -  Known TRUE acetylsalicylic acid (ASA) allergy;

          -  Use of glycoprotein (GP) IIb/IIIa inhibitors during the procedure visit within 30 days
             following the index procedure;

          -  Target lesion treated with a cryoplasty balloon at the time of the index procedure;

          -  Hemorrhagic stroke within six (6) months;

          -  Renal failure or chronic kidney disease with GFR ≤30 mL/min or MDRD GFR ≤30 mL/min per
             1.73 m2 (or serum creatinine ≥2.5 mg/L within 30 days of index procedure or treated
             with dialysis);

          -  Prior vascular surgery of the index limb;

          -  Current enrollment in another investigational device or drug study;

          -  After obtaining informed consent, at any point up to introduction of the OPC, the
             investigator determines the study subject is not appropriate for the study.

        Angiographic Inclusion Criteria:

          -  Reference vessel diameter (RVD) ≥ 4 mm and ≤ 7 mm for femoropopliteal arteries or ≥ 2
             mm and ≤ 4 mm for infrapopliteal arteries;

          -  Either single or multiple lesions in the SFA and/or popliteal artery or single or
             multiple lesions in the infrapopliteal arteries (AT, PT, peroneal);

          -  For single lesion treatment, minimum lesion length ≥ 20 mm;

          -  Minimum of one patent infrapopliteal vessel;

          -  Pre-intervention percent DS ≥ 70%.

        Angiographic Exclusion Criteria:

          -  Flow limiting dissection necessitating stent placement prior to OPC use;

          -  Post PTA residual stenosis ≥ 30% as visualized by treating physician;

          -  Perforation requiring a covered stent;

          -  For femoropopliteal target lesion or occlusion location extends distally beyond the P2
             region of the popliteal artery or infrapopliteal lesion or occlusion location is at or
             proximal to the origin of the trifurcation vessel or below the ankle (top of the talus
             bone);

          -  Target lesion within a fractured stent;

          -  Target lesion within a stent and restenosed two (2) or more times;

          -  Significant (≥ 50% DS) inflow lesion or occlusion left untreated in the ipsilateral
             Iliac, SFA, or popliteal artery proximal to the target lesion;

          -  A lesion treated distal to the target lesion results in compromising inline flow
             distal to the target lesion;

          -  Visible thrombus in the target artery or proximal to the target artery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Bunch, MD, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology Associates</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chris Schultz, BS, CCRA</last_name>
    <phone>971-506-7552</phone>
    <email>CSchultz@ECR-Inc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiology Associates</name>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Austin, RN</last_name>
      <phone>251-990-1936</phone>
      <email>MAustin@cardassoc.com</email>
    </contact>
    <investigator>
      <last_name>Frank T. Bunch, MD, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Vascular and Interventional</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela MacKay, RN, MSN</last_name>
      <phone>850-494-1108</phone>
      <email>angela.mackay@coastalvi.com</email>
    </contact>
    <investigator>
      <last_name>Huey McDaniel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70361</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deanna K Benoit, LPN</last_name>
      <phone>985-873-5613</phone>
      <email>Deanna.Benoit@cardio.com</email>
    </contact>
    <investigator>
      <last_name>Craig M. Walker, MD, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan Outpatient Vascular Institute</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Leyson-Fiel, BSN, RN</last_name>
      <phone>313-505-1296</phone>
      <email>ALeysonfiel@movidearborn.com</email>
    </contact>
    <investigator>
      <last_name>Elias Kassab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. John Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhonda Morin, RN</last_name>
      <phone>313-343-7536</phone>
      <email>Rhonda.Morin@stjohn.org</email>
    </contact>
    <investigator>
      <last_name>Thomas P. Davis, MD, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid-Michigan Heart &amp; Vascular Center</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Mook, RN, BSN</last_name>
      <phone>989-249-6432</phone>
      <email>emook@mmhavc.com</email>
    </contact>
    <investigator>
      <last_name>John M McClure II, MD, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novant Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Burdon</last_name>
      <phone>704-264-1400</phone>
      <email>rburdon@novanthealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Surgical Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Brown</last_name>
      <phone>423-778-7695</phone>
      <email>Laura.brown@universitysurgical.com</email>
    </contact>
    <investigator>
      <last_name>Mark Fugate, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kore Cardiovascular Research</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Manns</last_name>
      <phone>731-512-0104</phone>
      <email>dmanns@koreresearch.com</email>
    </contact>
    <investigator>
      <last_name>Elie Hage-Korban, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsville Memorial Hospital</name>
      <address>
        <city>Huntsville</city>
        <state>Texas</state>
        <zip>77340</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Terry, CCMA, CRC</last_name>
      <phone>903-723-8800</phone>
      <phone_ext>2379</phone_ext>
      <email>kristen.terry@graceresearchllc.com</email>
    </contact>
    <investigator>
      <last_name>Gaurav Aggarwala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Dallas Research Associates</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irfan Ullah, MBBS, CCRP</last_name>
      <phone>972-562-2345</phone>
      <email>irfan@ndresearch.com</email>
    </contact>
    <investigator>
      <last_name>Muhammad A Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates of East Texas</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Olson</last_name>
      <phone>903-595-2283</phone>
      <phone_ext>2105</phone_ext>
      <email>eolson@caet.net</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Carr, MD, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2015</study_first_submitted>
  <study_first_submitted_qc>June 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2015</study_first_posted>
  <last_update_submitted>June 7, 2017</last_update_submitted>
  <last_update_submitted_qc>June 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAD</keyword>
  <keyword>COPPER-A</keyword>
  <keyword>Peripheral Arterial Disease</keyword>
  <keyword>OPC</keyword>
  <keyword>Occlusion Perfusion Catheter</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Pressana</keyword>
  <keyword>Precision Delivery System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

